Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IM83
i
Other names:
IM83
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Beijing Imunopharm
Drug class:
GPC-3-targeted CAR-T immunotherapy
Related drugs:
‹
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
B010-A (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GLYCAR T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
B010-A (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GLYCAR T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
›
Associations
News
Trials
Filter by
Latest
6ms
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
P1, N=9, Not yet recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
6 months ago
New P1 trial • CAR T-Cell Therapy
|
cyclophosphamide • IM83
almost3years
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors (clinicaltrials.gov)
P1, N=12, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
almost 3 years ago
Clinical • New P1 trial • CAR T-Cell Therapy
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
|
GPC3 expression
|
IM83
over3years
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (clinicaltrials.gov)
P1, N=10, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
over 3 years ago
Clinical • New P1 trial • CAR T-Cell Therapy
|
GPC3 (Glypican 3)
|
GPC3 expression
|
IM83
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login